Anti-Inflammatory Supplements: An Evidence-Based Guide
Two compounds have solid human evidence, several have good mechanisms defeated by bioavailability, and the largest available effects are not supplements at all.
The Short Answer
Chronic low-grade inflammation is a genuine contributor to age-related disease rather than a wellness abstraction, and it is measurable. That makes this Pillar unusually testable: you can supplement, re-measure high-sensitivity CRP three months later, and get an answer. Applying that discipline shrinks the category considerably. Omega-3 fatty acids and curcumin in a bioavailable form have reasonable human data. Most of the rest have mechanism and no measurable effect at achievable doses.
What Chronic Inflammation Is, Briefly
Acute inflammation is a coordinated, resolving response to injury or infection. What matters for ageing is different: a persistent low-grade elevation of inflammatory signalling without an acute trigger, sometimes called inflammaging.
Its sources are largely structural. Visceral adipose tissue secretes inflammatory cytokines. Senescent cells release a pro-inflammatory secretory profile. Gut barrier permeability allows bacterial components into circulation. Sleep restriction raises inflammatory markers. Sustained hyperglycaemia and glycation contribute. Chronic psychological stress and low fitness both associate with higher inflammatory tone.
Notice that list. Almost every item is a structural or behavioural condition rather than a nutrient shortfall, which is the reason supplements occupy a narrower role in this Pillar than the marketing suggests. The Pillar 3 fundamentals article covers the biology at more length.
The Two With Real Human Evidence
Omega-3 fatty acids, EPA and DHA. The best-evidenced compound in the category. Trials consistently show dose-dependent reductions in triglycerides and modest reductions in inflammatory markers, and the cardiovascular outcome literature, while heterogeneous, is substantial.
The mechanism goes beyond simple displacement of arachidonic acid: EPA and DHA are substrates for specialised pro-resolving mediators, resolvins and protectins, which actively terminate inflammation rather than merely suppressing its initiation. That is a mechanistically distinct action and it is why omega-3 is not simply a weak anti-inflammatory.
Dose matters more than most people assume. Meaningful effects generally require 2 g or more of combined EPA and DHA daily, which is considerably more than a standard capsule provides. Check the EPA and DHA content on the label rather than the total fish oil weight, since a 1000 mg capsule commonly contains 300 mg of active fatty acids.
Curcumin, in a bioavailable formulation. Trials report reductions in inflammatory markers and symptomatic benefit in osteoarthritis at effect sizes that have been compared favourably to some conventional options in individual studies. The catch is absorption: plain curcumin is very poorly absorbed and rapidly conjugated. Formulations using piperine, phospholipid complexes, nanoparticles or micellar delivery achieve substantially higher plasma levels, and trial results largely come from these rather than from plain turmeric powder.
Mechanism Without Reachable Concentration
| Compound | Mechanism | Problem |
|---|---|---|
| Resveratrol | NF-kB inhibition in vitro | Extensive conjugation; free plasma levels far below experimental concentrations |
| Quercetin | Multiple inflammatory pathways in vitro | Poor bioavailability; substantial CYP3A4 and P-glycoprotein interactions |
| EGCG from green tea | NF-kB and cytokine modulation | Low absorption; hepatotoxicity reports at high-dose extracts |
| Sulforaphane | Nrf2 activation, well characterised | Requires myrosinase; supplement forms vary greatly in yield |
| Boswellia | 5-lipoxygenase inhibition | Reasonable osteoarthritis data; standardisation varies widely |
| Ginger | Prostaglandin pathway effects | Modest effects; better evidence for nausea than inflammation |
| Bromelain | Proteolytic and inflammatory effects | Thin human data outside post-surgical contexts |
The pattern is consistent enough to be a rule: a polyphenol demonstrating NF-kB inhibition in cell culture at micromolar concentrations, when oral dosing produces nanomolar free plasma levels, is not doing in a person what it did in the dish. Boswellia and sulforaphane are the most interesting partial exceptions, the former on osteoarthritis symptom data and the latter on a well-characterised Nrf2 mechanism with formulation as the limiting factor.
Compounds With Specific Rather Than General Cases
Vitamin D, where status is low. Immune modulation is one of vitamin D's better-established non-skeletal roles, and correction where status is genuinely low is reasonable. Supplementation in replete people has repeatedly failed to produce the benefits observational data suggested, which is a useful reminder about association.
Magnesium. Low intake is associated with higher CRP in population data, and intake is below recommendations for a large fraction of people. Inexpensive and reasonable.
Fibre and fermentable substrate. Not usually filed as anti-inflammatory and probably more effective than most things that are. Short-chain fatty acids from bacterial fermentation, principally butyrate, support gut barrier integrity and have direct immunomodulatory effects. This connects Pillar 3 to Pillar 6 tightly.
Specific probiotic strains. Strain-specific effects on inflammatory markers exist. Genus and species alone are not enough, and a product without a strain designation cannot be matched to any trial.
Low-dose aspirin. Worth naming because it is the anti-inflammatory intervention with the largest cardiovascular outcome literature, and current guidance has moved away from routine primary prevention use because bleeding risk offsets benefit in low-risk people. That is a clinical decision rather than a supplement one.
What Actually Lowers Inflammatory Markers Most
Ranked by expected effect on measured markers, which inverts the usual presentation of this topic.
Reducing visceral adiposity. The single largest modifiable contributor for most people with excess adiposity. Adipose tissue is an active source, so reducing it reduces production rather than suppressing signalling.
Regular exercise. Consistently associated with lower CRP and interleukin-6 in cross-sectional and intervention data, with an acute rise after hard sessions that resolves.
Adequate sleep. Restriction raises inflammatory markers measurably in controlled studies, and sleep-disordered breathing is an independent contributor.
Not smoking. Large and unambiguous.
Periodontal health. Chronic periodontal inflammation contributes to systemic markers and is frequently unaddressed. A dental question with a Pillar 3 answer.
Diet pattern rather than single nutrients. Whole-diet indices associate with inflammatory markers more strongly than any individual food or compound.
Alcohol reduction, where intake is high.
Supplements fall below all of these. That does not make them useless, and it does mean a person supplementing without addressing adiposity, sleep and activity is working on the smallest available term.
A Defensible Stack and How to Test It
Core: omega-3 at 2 g or more combined EPA and DHA daily, checking the label for actual fatty acid content. Adequate fibre, aiming toward 30 g daily from food. Vitamin D and magnesium where status or intake is low.
If there is a symptomatic inflammatory complaint, particularly joint pain: a bioavailable curcumin formulation, or boswellia, tried singly for three months.
Skip: proprietary anti-inflammatory blends with a dozen polyphenols at undisclosed doses, high-dose green tea extract given hepatotoxicity reports, and anything sold on cell-culture NF-kB data without human pharmacokinetics.
How to test it, which is the part usually omitted. Measure high-sensitivity CRP before starting and again at three months, in the absence of acute illness, since a single infection can raise it several-fold and make the comparison meaningless. If CRP has not moved and symptoms have not changed, the stack is not doing what it was added for.
This Pillar is one of the few where a consumer can genuinely audit their own supplementation with an inexpensive test. Doing so is more informative than any amount of reading about mechanisms.
The AEONNN Perspective
Pillar 3 is where AEONNN's Pharmacokinetics layer overrides the most mechanistic claims. Cell-culture NF-kB inhibition is abundant across polyphenols and mostly unreachable at oral doses, and the platform grades on achievable plasma concentration rather than on demonstrated mechanism.
The Quality layer is decisive for the two compounds that do work. Omega-3 requires reading EPA and DHA content rather than total oil weight, and curcumin's trial results come from bioavailability-enhanced formulations rather than from plain extract. Recommending the compound without specifying the formulation would be recommending something that does not work.
Pillar 3 also has the strongest cross-Pillar coupling in the Matrix. Visceral adiposity in Pillar 4, sleep in Pillar 9 and gut barrier integrity in Pillar 6 are all upstream sources, which is why the platform will often answer an inflammatory marker with a recommendation from another Pillar. And because high-sensitivity CRP is inexpensive and responsive, this is the Pillar where the Insight Protocol can most cleanly close the loop on whether a change worked.
Pillar Matrix mapping
Database Matrix layers
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Pharmacokinetics Layer (HMDB, PubChem)
- Mechanistic Layer (KEGG, Reactome, UniProt)
- Quality / Formulation Layer (ConsumerLab, Labdoor)
Frequently Asked
What is the best anti-inflammatory supplement?
Omega-3 fatty acids, at 2 g or more of combined EPA and DHA daily. They reduce inflammatory markers and serve as substrates for specialised pro-resolving mediators that actively terminate inflammation.
How much omega-3 do I need?
Meaningful effects generally require 2 g or more of combined EPA and DHA. Check the label for actual EPA and DHA content, since a 1000 mg fish oil capsule commonly contains around 300 mg of active fatty acids.
Does curcumin work for inflammation?
In bioavailable formulations, yes, with trial support in osteoarthritis and on inflammatory markers. Plain curcumin is very poorly absorbed, and trial results come from enhanced formulations rather than turmeric powder.
Why do most polyphenol supplements fail?
They demonstrate NF-kB inhibition in cell culture at micromolar concentrations while oral dosing produces nanomolar free plasma levels. The mechanism is real and the concentration is unreachable.
What lowers inflammation most?
Reducing visceral adiposity, then regular exercise, adequate sleep, not smoking and periodontal health. All of these exceed any supplement effect, and adipose tissue is an active source rather than a passive store.
Does fibre reduce inflammation?
Probably more than most compounds marketed for it. Bacterial fermentation produces short-chain fatty acids, principally butyrate, which support gut barrier integrity and have direct immunomodulatory effects.
How do I know if my anti-inflammatory stack works?
Measure high-sensitivity CRP before starting and at three months, away from acute illness. If CRP has not moved and symptoms are unchanged, the stack is not doing what it was added for.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.